ERBB2 and breast carcinoma: Genomic assays, such as the 21-gene recurrence score [28] and the 70-gene signature [29, 30], have become a popular method to identify patients where chemotherapy can safely be omitted, particularly in ER+/HER2− breast cancer [28, 31–33].